Ekso Bionics Holdings Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Ekso Bionics Holdings, Inc. (EKSO) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-11.33-15.20-15.08-9.76-15.83-12.13-26.99
Depreciation & Amortization1.611.700.891.020.620.691.52
Stock Based Compensation1.632.242.732.502.580.000.00
Change in Working Capital-2.53-0.58-2.58-0.931.12-1.950.53
Change in Accounts Receivable-1.97-1.21-0.07-1.621.750.000.00
Change in Inventory0.260.23-1.40-0.750.380.000.00
Change in Accounts Payable-0.29-1.31-0.101.61-0.400.000.00
Change in Other Working Capital-0.53-0.29-0.500.13-0.630.000.00
Other Operating Activities0.77-0.282.750.136.27-2.510.12
Net Cash from Operating Activities-9.85-12.05-14.69-11.16-8.76-15.77-22.17
Investing Activities
Capital Expenditures-0.04-0.160.19-0.060.000.06-0.13
Acquisitions0.000.00-5.000.000.000.000.00
Net Cash from Investing Activities-0.04-0.16-5.18-0.060.00-0.06-0.13
Financing Activities
Debt Repayment-1.25-0.310.000.00-1.28-2.38-2.17
Common Stock Issued9.020.660.0037.307.0821.194.45
Net Cash from Financing Activities7.770.350.0038.7110.7019.042.27
Summary
Effect of Forex Changes on Cash-0.03-0.02-0.020.050.040.01-0.14
Net Change in Cash-2.11-11.89-19.8627.501.993.22-20.02
Cash at Beginning of Period8.6420.5340.4112.8610.877.6627.81
Cash at End of Period6.498.6440.4140.4112.8610.877.66
Free Cash Flow-9.88-12.21-14.86-11.22-8.76-15.83-22.30
Supplemental Disclosures
Interest Paid0.180.190.130.100.010.020.46
Income Taxes Paid0.010.050.010.000.110.310.02